Fibrogen announces results for matterhorn, a phase 3 clinical study of roxadustat for the treatment of anemia in patients with myelodysplastic syndromes (mds)

San francisco, may 05, 2023 (globe newswire) -- fibrogen, inc. (nasdaq: fgen) today announced that matterhorn, a phase 3 clinical study of roxadustat for treatment of anemia in patients with transfusion-dependent lower risk myelodysplastic syndromes (mds) did not meet its primary efficacy endpoint. the proportion of patients who achieved red blood cell transfusion independence in the first 28 weeks was 47.5% for the roxadustat arm compared to 33.3% for placebo (p=0.217).
FGEN Ratings Summary
FGEN Quant Ranking